AMBRA1 and FAK1: crosstalking for improved targeted therapy in melanoma.

Mol Cell Oncol

Melanoma Research Team, Cell Stress and Survival Unit, Danish Cancer Society Research Center, Copenhagen, Denmark.

Published: July 2021

Unlabelled: Through genetically engineered mouse models of melanoma, we identified Autophagy/beclin 1 regulator 1 (Ambra1) as novel tumor-suppressor in melanoma. In these settings, loss of associated with the hyperactivation of focal adhesion kinase 1 (Fak1) signaling, the inhibition of which resulted in reduced tumor growth and invasiveness. We therefore propose FAK1 inhibition for current melanoma therapy in AMBRA1-low tumors.

Abbreviations: AKT, serine/threonine kinase 1; AMBRA1, autophagy/beclin 1 regulator 1; BRAF, v-raf murine sarcoma viral oncogene homolog; BRAFi, BRAF inhibitor; CCLE, Cancer Cell Line Encyclopedia;g ESTDAB, European Searchable Tumor Line Database; FAK1, focal adhesion kinase 1; FAKi, FAK1 inhibitor; LMC, Leeds Melanoma Cohort; MEK, MAPK/ERK kinase; PP2A, protein phosphatase 2A; PTEN, phosphatase and tensin homolog; TCGA-SKCM, The Cancer Genome Atlas - Skin Cutaneous Melanoma; YAP, yes-associated protein 1.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489905PMC
http://dx.doi.org/10.1080/23723556.2021.1949955DOI Listing

Publication Analysis

Top Keywords

autophagy/beclin regulator
8
focal adhesion
8
adhesion kinase
8
melanoma
6
ambra1 fak1
4
fak1 crosstalking
4
crosstalking improved
4
improved targeted
4
targeted therapy
4
therapy melanoma
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!